Funding a Smoking Cessation Program for Crohn’s Disease: An Economic Evaluation

[1]  Tim Lancaster,et al.  Individual behavioural counselling for smoking cessation. , 2017, The Cochrane database of systematic reviews.

[2]  N. Pedersen,et al.  Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study. , 2014, Journal of Crohn's & colitis.

[3]  G. Kaplan,et al.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. , 2014, Canadian journal of gastroenterology & hepatology.

[4]  Robert D Gibbons,et al.  Varenicline, smoking cessation, and neuropsychiatric adverse events. , 2013, The American journal of psychiatry.

[5]  Subrata Ghosh,et al.  Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. , 2013, Gastroenterology.

[6]  C. Yunis,et al.  Effects of Varenicline on Smoking Cessation in Adults With Stably Treated Current or Past Major Depression , 2013, Annals of Internal Medicine.

[7]  R. Perera,et al.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.

[8]  M. Sans,et al.  High smoking cessation rate in Crohn's disease patients after physician advice--the TABACROHN Study. , 2013, Journal of Crohn's & colitis.

[9]  G. Kaplan,et al.  Environment and the inflammatory bowel diseases. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[10]  A. Bitton,et al.  Inflammatory bowel disease: a Canadian burden of illness review. , 2012, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[11]  C. Bernstein,et al.  Direct Medical Cost of Managing IBD Patients: A Canadian Population‐based Study , 2012, Inflammatory bowel diseases.

[12]  M. Sans,et al.  330 High Smoking Cessation Rate in Crohns Disease Patients Attending a Multicenter Anti-Tobacco Program: the TABACROHN Study , 2012 .

[13]  K. Fox,et al.  Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis , 2012, Advances in Therapy.

[14]  G. Kaplan,et al.  Assessment of Variables Associated with Smoking Cessation in Crohn’s Disease , 2012, Digestive Diseases and Sciences.

[15]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[16]  L. Cipriano,et al.  Guidelines for the Economic Evaluation of Health Technologies: Canada , 2012 .

[17]  Kenneth W Lin,et al.  Nicotine receptor partial agonists for smoking cessation. , 2011, American family physician.

[18]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[19]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[20]  G. Kaplan,et al.  Environmental risk factors for inflammatory bowel disease. , 2010, Gastroenterology & hepatology.

[21]  P. Munkholm,et al.  Overall and cause‐specific mortality in Crohn's disease: A meta‐analysis of population‐based studies , 2009, Inflammatory bowel diseases.

[22]  G. Kaplan,et al.  Systematic review: the short‐term and long‐term efficacy of adalimumab following discontinuation of infliximab , 2009, Alimentary pharmacology & therapeutics.

[23]  R. Fedorak,et al.  Does smoking reduce infliximab's effectiveness against Crohn's disease? , 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[24]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[25]  P. Tekkis,et al.  The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies , 2008, International Journal of Colorectal Disease.

[26]  William J. Tremaine,et al.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 , 2007, Inflammatory bowel diseases.

[27]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[28]  Beverly M. Calkins DHSc.  A meta-analysis of the role of smoking in inflammatory bowel disease , 2005, Digestive Diseases and Sciences.

[29]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[30]  Samir A. Shah,et al.  Risk of early surgery for Crohn's disease: implications for early treatment strategies , 2003, American Journal of Gastroenterology.

[31]  I Campbell,et al.  Nicotine replacement therapy in smoking cessation. , 2003, Thorax.

[32]  F. Carbonnel,et al.  Smoking cessation and the course of Crohn's disease: an intervention study. , 2001, Gastroenterology.

[33]  R. Cohen,et al.  The cost of hospitalization in Crohn's disease , 2000, American Journal of Gastroenterology.

[34]  B. Feagan,et al.  An Evaluation of Utility Measurement in Crohn's Disease , 1997, Inflammatory bowel diseases.

[35]  T. Svensson,et al.  Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms , 1997, Psychopharmacology.

[36]  J R Hughes,et al.  Smoking cessation among self-quitters. , 1992, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[37]  B. Calkins.  A meta-analysis of the role of smoking in inflammatory bowel disease , 1989, Digestive diseases and sciences.

[38]  G. H. Moore,et al.  Consumer Price Index , 1993 .